Advertisement

Topics

Mesoblast Company Profile

09:05 EDT 20th September 2017 | BioPortfolio

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.


News Articles [8 Associated News Articles listed on BioPortfolio]

Mesoblast (MSB) - Confident management

Edison Investment Research - Pharmaceutical & healthcare - Mesoblast: Mesoblast has raised cash and cleared an interim futility analysis of its Phase III heart failure (HF) trial, will complete enrolm...

Mesoblast Heart Failure Trial Delivers Positive Interim Results

May 4, 2017 (Investorideas.com Newswire) Mesoblast Ltd., an Australia-based regenerative medicine company currently in a Phase 3 clinical trial in chronic heart failure, has received successful interi...

Deals this week: MyoKardia, Kala Pharmaceuticals, Mesoblast

MyoKardia has announced plans to issue more than nine million shares of its common stock priced at $13.3 a share, to raise $122.15m in gross proceeds.

XFRA LWB: AUSSETZUNG/SUSPENSION

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL MESOBLAST LT...

Stem Cell Therapy for Heart Failure Gets a Gold-Standard Trial

(Scientific American) – A cadre of scientists and companies is now trying to prevent or reverse cardiac damage by infusing a cocktail of stem cells into weakened hearts. One company, Melbourne, ...

Pro-Trader Daily: Featured Company News - Bio-Techne Acquires Trevigen in an All-cash Deal

Research Desk Line-up: Mesoblast Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

Mesoblast Ltd MSB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27072017] Prices from USD $250

SummaryMesoblast Ltd Mesoblast is a regenerative medicine company, which develops regenerative cellbased products. Its pipeline product candidates include MPC150IM, which is under development for the ...

Global Regenerative Medicine Market 2012 2022 [Report Updated: 01032017] Prices from USD $3120

SummaryBased on products type, the report describes major products type share of regional market. Products mentioned as follows: By Type Cell Therapy Tissue Engineering Biomaterial Others...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

Patients under the age of 5, with a diagnosis of hypoplastic left heart syndrome (HLHS), unbalanced atrioventricular canal (uAVC), or borderline left heart who are undergoing staged LV rec...

Companies [2 Associated Companies listed on BioPortfolio]

Mesoblast Limited

Mesoblast Limited (ASX: MSB; USADR: MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a serie...

Mesoblast

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology ai...

More Information about "Mesoblast" on BioPortfolio

We have published hundreds of Mesoblast news stories on BioPortfolio along with dozens of Mesoblast Clinical Trials and PubMed Articles about Mesoblast for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mesoblast Companies in our database. You can also find out about relevant Mesoblast Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Corporate Database Quicklinks



Searches Linking to this Company Record